Cite
HARVARD Citation
Salles, G. et al. (2020). Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet oncology. 21 (7), pp. 978-988. [Online].